Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect the biotech sector to thrive over time as our global population ages and demands more medical treatments, the Market Vectors Biotech ETF
If you're familiar with ETFs and think that the BBH ticker looks familiar, but the fund's name doesn't, you're right. This ETF is one of several replacing Merrill Lynch-based HOLDRs which had some problems that these funds don't.
ETFs often sport lower expense ratios than their mutual fund cousins. The Market Vectors ETF's expense ratio -- its annual fee -- is a low 0.35%.
This ETF doesn't have much of a performance record yet, as it's just a few weeks old. It's relatively small, too, so if you're thinking of buying, beware of occasionally large spreads between its bid and ask prices. You might want to just keep an eye on it as it matures a bit, or you might want to be an early investor. Remember that as with most investments, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
What's in it?
Several of the companies this ETF includes performed well over the past year. Regeneron Pharmaceuticals surged 137%, for example, buoyed by a huge revenue jump with the successful launch of its age-related macular degeneration drug, Eylea.
Other companies didn't do as well, but could see improvement in the years to come. Amylin Pharmaceuticals
Human Genome Sciences
The big picture
Biotechnology can be a volatile arena, with companies surging or plunging as their products try to pass approval hurdles and succeed in the market. But demand for biotechnology's goods isn't going away anytime soon. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.
Longtime Fool contributor Selena Maranjian holds no position in any company mentioned. Click here to see her holdings and a short bio. The Motley Fool owns shares of Dendreon and Exelixis. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Healthcare Stocks to Buy in December
Now could be the perfect time to add to your portfolio healthcare stocks that can benefit from aging baby boomers and regulatory approvals.
Is Exelixis, Inc. a Buy?
This biotech stock is up close to 80% in 2017. But can Exelixis go even higher?
Better Buy: Exelixis, Inc. vs. Novartis AG
Which stock wins in a head-to-head matchup between a rising biotech star and an established big pharma leader?